Gliclazide MR in Chronic Kidney Disease

Safety Profile in CKD

Gliclazide MR has a favorable safety profile in patients with impaired renal function, with a low incidence of hypoglycemic episodes, and is preferred over first-generation sulfonylureas due to its minimal dose adjustment requirements in renal impairment 1
Unlike first-generation sulfonylureas, gliclazide MR does not have active metabolites that increase hypoglycemia risk in reduced kidney function, making it a safer option 1

The American Journal of Kidney Diseases recommends gliclazide MR as an alternative agent when other preferred medications cannot be used or when additional glycemic control is needed in patients with chronic kidney disease 1
Current guidelines recommend a stepwise approach for glycemic management in CKD, with metformin as first-line therapy for patients with T2D, CKD, and eGFR ≥30 ml/min/1.73 m², and SGLT2 inhibitors for patients with T2D, CKD, and eGFR ≥20 ml/min/1.73 m² 2, 3, 4
GLP-1 receptor agonists are recommended for patients who have not achieved glycemic targets despite metformin and SGLT2i, or who cannot use these medications 5, 6

Regular monitoring of glycemic control is recommended, with HbA1c measurements twice per year or more frequently if targets are not met, and consideration of more frequent blood glucose monitoring when using sulfonylureas including gliclazide MR in patients with CKD to detect and prevent hypoglycemia 6, 1
The Kidney International guidelines note that HbA1c measurement accuracy declines with advanced CKD (G4-G5), particularly in dialysis patients 6